US FDA again extends comment deadline for generic user fee proposal
This article was originally published in SRA
The US Food and Drug Administration has again extended the comment deadline for stakeholder feedback on its proposed user fee programme for generic drugs; comments will now be accepted until 1 August1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.